Figure 4
From: A Framework for Decision-Making for Mass Distribution of Mectizan® in Areas Endemic for Loa loa
Estimated rates of lifetime blindness (per 1000 population) and of death and chronic disability from L. loa encephalopathy, under conditions of 1) no mass treatment with Mectizan®; 2) mass treatment with no risk reduction strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40. Data are shown for two levels of loiasis co-endemicity, both with highly endemic onchocerciasis. Similar patterns are observed in areas of low onchocerciasis endemicity (data not shown).